Bamco Inc Zentalis Pharmaceuticals, Inc. Call Options Transaction History
Bamco Inc
- $35.2 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ZNTL
# of Institutions
123Shares Held
59.9MCall Options Held
0Put Options Held
22K-
Matrix Capital Management Company, LP Waltham, MA14MShares$19.7 Million8.42% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.79 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.48MShares$4.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$4.07 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.8MShares$3.95 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $80.3M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...